한글목차

피부근염 치료 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 9억 1,000만 달러에서 2026년에는 9억 8,000만 달러로, CAGR 7.2%로 확대될 전망입니다. 지난 몇 년간 성장 요인으로는 자가면역질환에 대한 인식 개선, 코르티코스테로이드의 보급, 류마티스내과 진료소 확대, 병원 기반 면역요법, 지지요법의 발전 등을 꼽을 수 있습니다.

피부근염 치료 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 12억 8,000만 달러에 달하고, CAGR은 6.8%가 될 전망입니다. 예측 기간의 성장 요인으로는 생물학적 제제 파이프라인의 확대, 정밀 면역학의 발전, 조기 자가면역질환 스크리닝, 맞춤형 치료 프로토콜의 확립, 전문 클리닉의 증가 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 생물학적 제제 요법 사용 증가, 면역억제제 의존도 증가, 병용 치료 접근법 확대, 장기 물리치료 도입 증가, 조기 진단 및 질병 모니터링 개선 등을 꼽을 수 있습니다.

자가면역질환의 유병률 증가는 향후 몇 년 동안 피부근육염 치료 시장의 성장을 견인할 것으로 예상됩니다. 자가면역질환은 우리 몸의 면역체계가 자신의 건강한 세포와 조직을 잘못 공격하여 발생합니다. 자가면역질환의 유병률 증가는 진단 방법의 개선, 인지도 향상, 환경적 요인에 기인하며, 이러한 요인들이 복합적으로 작용하여 검출률과 보고 건수 증가로 이어지고 있습니다. 피부근육염 치료는 유해한 면역반응을 억제하고 환자의 삶의 질을 향상시키는 표적 치료제를 제공함으로써 이러한 추세에 대응하고 있습니다. 예를 들어, 미국 비영리단체 '자가면역연구소'에 따르면, 2024년 2월 기준 선진국의 자가면역질환 유병률은 전체 인구의 5-10%에 달합니다. 따라서 자가면역질환의 증가는 피부근육염 치료 시장의 성장을 촉진하고 있습니다.

피부근육염 치료 시장의 주요 기업들은 기존 치료의 광범위한 면역 억제를 피하고 보다 안전하고 표적화된 치료법에 대한 수요 증가에 대응하기 위해 선택적 보체 경로 억제제와 같은 혁신적인 솔루션 개발에 주력하고 있습니다. 선택적 보체 경로 억제제는 피부근육염에서 염증을 촉진하는 보체 캐스케이드의 구성요소를 특이적으로 억제하여 기존 면역억제제보다 정밀한 작용기전을 제공합니다. 예를 들어, 2025년 2월, 미국에 본사를 둔 임상 단계의 생명공학 기업 NovelMed Therapeutics Inc.는 보체 Bb 인자를 대상으로 하는 대체 보체 경로의 고도로 선택적인 억제제인 Ruxoprubart(NM8074)에 대한 임상 2상 시험을 개시하기 위해 미국 식품의약국(FDA)으로부터 허가를 받았습니다. 룩소프레버트는 주요 염증 유발 인자를 억제하여 면역반응을 조절하고, 선택적 면역기능과 세균 제거 등 필수 면역기능을 유지하면서 광범위 보체억제제 대비 위험을 최소화할 수 있습니다. 이 치료법은 피부근육염 환자에서 유효성과 안전성을 평가받고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Dermatomycosis treatment involves the use of antifungal therapies to eliminate fungal infections of the skin. Mild to moderate infections are typically treated with topical antifungal creams or ointments such as clotrimazole, miconazole, or terbinafine. In more severe or resistant cases, oral antifungal medications like fluconazole or itraconazole may be prescribed.

The main treatment types for dermatomycosis include pharmacological treatments, immunosuppressants, corticosteroids, biologics, and physical therapy. Pharmacological treatments use medications to manage symptoms and address the underlying cause of the disease. Routes of administration include oral, intravenous, and subcutaneous methods, with patient demographics categorized by age and gender. Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies, serving end-users such as hospitals, home care providers, specialty clinics, and others.

Tariffs have increased costs in the dermatomyositis treatment market by impacting imports of immunosuppressants, biologics, corticosteroids, and intravenous drug delivery materials. Biologic therapies and IVIG treatments are most affected, especially in North America and Europe where biologics are heavily imported. Hospital pharmacies face rising procurement expenses. On the positive side, tariffs are encouraging regional biologics manufacturing and pharmaceutical self-sufficiency.

The dermatomyositis treatment market research report is one of a series of new reports from The Business Research Company that provides dermatomyositis treatment market statistics, including dermatomyositis treatment industry global market size, regional shares, competitors with a dermatomyositis treatment market share, detailed dermatomyositis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the dermatomyositis treatment industry. This dermatomyositis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dermatomyositis treatment market size has grown strongly in recent years. It will grow from $0.91 billion in 2025 to $0.98 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to autoimmune disease recognition, corticosteroid availability, rheumatology clinic expansion, hospital-based immunotherapy, supportive care development.

The dermatomyositis treatment market size is expected to see strong growth in the next few years. It will grow to $1.28 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to biologic pipeline expansion, precision immunology, early autoimmune screening, personalized treatment protocols, specialty clinic growth. Major trends in the forecast period include increased use of biologic therapies, growing reliance on immunosuppressive drugs, expansion of combination treatment approaches, rising adoption of long-term physical therapy, improved early diagnosis and disease monitoring.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the dermatomyositis treatment market in the coming years. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues. The rising prevalence of autoimmune conditions is attributed to improved diagnostic methods, greater awareness, and environmental factors, which collectively lead to higher detection rates and reported cases. Dermatomyositis treatments help address this trend by providing targeted therapies that reduce harmful immune activity and improve quality of life for affected patients. For instance, in February 2024, according to the Autoimmune Institute, a US-based nonprofit organization, autoimmune diseases collectively affect 5-10% of the population in industrialized countries. Therefore, the increasing prevalence of autoimmune diseases is boosting growth in the dermatomyositis treatment market.

Major companies in the dermatomyositis treatment market are focusing on developing innovative solutions, such as selective complement-pathway inhibitors, to meet the rising demand for safer, more targeted therapies that avoid the broad immunosuppression associated with traditional treatments. Selective complement-pathway inhibitors specifically block components of the complement cascade that drive inflammation in dermatomyositis, offering a more precise mechanism than conventional immunosuppressive agents. For example, in February 2025, NovelMed Therapeutics Inc., a US-based clinical-stage biotech company, received U.S. Food and Drug Administration (FDA) clearance to initiate a Phase II trial of Ruxoprubart (NM8074), a highly selective blocker of the alternative complement pathway targeting Factor Bb. Ruxoprubart modulates the immune response by reducing key inflammatory drivers while preserving essential immune functions, such as opsonization and bacterial clearance, potentially minimizing risks compared to broader complement blockers. The therapy is being evaluated for efficacy and safety in dermatomyositis patients.

In April 2025, Syneron Bio, a China-based biotechnology company, partnered with AstraZeneca to co-develop and commercialize innovative oral peptide therapies for chronic and autoimmune conditions. This collaboration combines Syneron Bio's proprietary macrocyclic peptide technology with AstraZeneca's global drug development expertise. AstraZeneca is a UK-based pharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory diseases

Major companies operating in the dermatomyositis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Bausch Health Companies Inc., Biotest AG, Galapagos NV, argenx SE, Roivant Sciences Ltd., Kymera Therapeutics Inc., Cabaletta Bio Inc., ImmunoForge Inc., NovelMed Therapeutics Inc., Corbus Pharmaceuticals Holdings Inc.

North America was the largest region in the dermatomyositis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatomyositis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dermatomyositis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dermatomycosis treatment market consists of revenues earned by entities by providing services such as natural and herbal remedies, antifungal shampoos, and immune-modulating treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The dermatomycosis treatment market also includes sales of antifungal nail lacquers, oral suspensions, and pediatric formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dermatomyositis Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses dermatomyositis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dermatomyositis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The dermatomyositis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Treatment Type: Pharmacological Treatments; Immunosuppressants; Corticosteroids; Biologics; Physical Therapy
• 2) By Route Of Administration: Oral; Intravenous; Subcutaneous
• 3) By Patient Demographics: Age Group; Gender
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Pharmacological Treatments: Antimalarials; Antiviral Agents; Muscle Relaxants; Analgesics
• 2) By Immunosuppressants: Methotrexate; Azathioprine; Mycophenolate Mofetil; Cyclophosphamide
• 3) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone
• 4) By Biologics: Rituximab; Intravenous Immunoglobulin (IVIG); Tocilizumab; Abatacept
• 5) By Physical Therapy: Stretching Exercises; Strength Training; Aerobic Conditioning; Occupational Therapy
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; Bristol-Myers Squibb Company; AstraZeneca plc; Novartis AG; GlaxoSmithKline plc; Eli Lilly and Company; Amgen Inc.; Fresenius SE & Co. KGaA; Bausch Health Companies Inc.; Biotest AG; Galapagos NV; argenx SE; Roivant Sciences Ltd.; Kymera Therapeutics Inc.; Cabaletta Bio Inc.; ImmunoForge Inc.; NovelMed Therapeutics Inc.; Corbus Pharmaceuticals Holdings Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Dermatomyositis Treatment Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Dermatomyositis Treatment Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Dermatomyositis Treatment Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Dermatomyositis Treatment Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Increased Use Of Biologic Therapies
  • 4.2.2 Growing Reliance On Immunosuppressive Drugs
  • 4.2.3 Expansion Of Combination Treatment Approaches
  • 4.2.4 Rising Adoption Of Long-Term Physical Therapy
  • 4.2.5 Improved Early Diagnosis And Disease Monitoring

5. Dermatomyositis Treatment Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Homecare Settings
• 5.4 Rehabilitation Centers
• 5.5 Research Institutions

6. Dermatomyositis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Dermatomyositis Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Dermatomyositis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Dermatomyositis Treatment Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Dermatomyositis Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Dermatomyositis Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Dermatomyositis Treatment Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Dermatomyositis Treatment Market Segmentation

• 9.1. Global Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pharmacological Treatments, Immunosuppressants, Corticosteroids, Biologics, Physical Therapy
• 9.2. Global Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Intravenous, Subcutaneous
• 9.3. Global Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Age Group, Gender
• 9.4. Global Dermatomyositis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
• 9.5. Global Dermatomyositis Treatment Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Clinics, Other End Users
• 9.6. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Pharmacological Treatments, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antimalarials, Antiviral Agents, Muscle Relaxants, Analgesics
• 9.7. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide
• 9.8. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone
• 9.9. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Rituximab, Intravenous Immunoglobulin (IVIG), Tocilizumab, Abatacept
• 9.10. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Physical Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Stretching Exercises, Strength Training, Aerobic Conditioning, Occupational Therapy

10. Dermatomyositis Treatment Market Regional And Country Analysis

• 10.1. Global Dermatomyositis Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Dermatomyositis Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Dermatomyositis Treatment Market

• 11.1. Asia-Pacific Dermatomyositis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Dermatomyositis Treatment Market

• 12.1. China Dermatomyositis Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Dermatomyositis Treatment Market

• 13.1. India Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Dermatomyositis Treatment Market

• 14.1. Japan Dermatomyositis Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Dermatomyositis Treatment Market

• 15.1. Australia Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Dermatomyositis Treatment Market

• 16.1. Indonesia Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Dermatomyositis Treatment Market

• 17.1. South Korea Dermatomyositis Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Dermatomyositis Treatment Market

• 18.1. Taiwan Dermatomyositis Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Dermatomyositis Treatment Market

• 19.1. South East Asia Dermatomyositis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Dermatomyositis Treatment Market

• 20.1. Western Europe Dermatomyositis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Dermatomyositis Treatment Market

• 21.1. UK Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Dermatomyositis Treatment Market

• 22.1. Germany Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Dermatomyositis Treatment Market

• 23.1. France Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Dermatomyositis Treatment Market

• 24.1. Italy Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Dermatomyositis Treatment Market

• 25.1. Spain Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Dermatomyositis Treatment Market

• 26.1. Eastern Europe Dermatomyositis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Dermatomyositis Treatment Market

• 27.1. Russia Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Dermatomyositis Treatment Market

• 28.1. North America Dermatomyositis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Dermatomyositis Treatment Market

• 29.1. USA Dermatomyositis Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Dermatomyositis Treatment Market

• 30.1. Canada Dermatomyositis Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Dermatomyositis Treatment Market

• 31.1. South America Dermatomyositis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Dermatomyositis Treatment Market

• 32.1. Brazil Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Dermatomyositis Treatment Market

• 33.1. Middle East Dermatomyositis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Dermatomyositis Treatment Market

• 34.1. Africa Dermatomyositis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Dermatomyositis Treatment Market, Segmentation By Treatment Type, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Dermatomyositis Treatment Market Regulatory and Investment Landscape

36. Dermatomyositis Treatment Market Competitive Landscape And Company Profiles

• 36.1. Dermatomyositis Treatment Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Dermatomyositis Treatment Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Dermatomyositis Treatment Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

37. Dermatomyositis Treatment Market Other Major And Innovative Companies

• Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Bausch Health Companies Inc., Biotest AG, Galapagos NV, argenx SE, Roivant Sciences Ltd., Kymera Therapeutics Inc., Cabaletta Bio Inc., ImmunoForge Inc., NovelMed Therapeutics Inc., Corbus Pharmaceuticals Holdings Inc.

38. Global Dermatomyositis Treatment Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Dermatomyositis Treatment Market

40. Dermatomyositis Treatment Market High Potential Countries, Segments and Strategies

• 40.1 Dermatomyositis Treatment Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Dermatomyositis Treatment Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Dermatomyositis Treatment Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer